Reference, not advice. Triptorelin and gonadorelin are prescription medicines used under specialist supervision. This page describes what the evidence shows. It publishes no doses, gives no guidance on use, and does not replace a prescriber. Vallydia does not sell, supply or link to either compound.
Both act on the same receptor, with opposite results. The deciding factor isn't the molecule but the rhythm.
In research-peptide shops, both compounds appear under the same heading: "testosterone and fertility support". For triptorelin, that heading is graded F in our register. The reason isn't weak evidence. It's the opposite: the evidence is so strong that we know the effect runs the other way. Triptorelin is approved precisely because it shuts down sex-hormone production. That is how it treats hormone-driven prostate cancer.
The hypothalamus releases GnRH in pulses. Each pulse tells the pituitary to release LH and FSH, which drive the testes or ovaries to make testosterone or oestrogen.
When the signal stops pulsing and becomes constant, the pituitary stops listening. Its GnRH receptors desensitise and downregulate, LH and FSH fall, and sex-hormone production shuts down. It is a reversible, medical "castration".
The flare matters clinically. In prostate cancer it can briefly feed the tumour, and it is managed with antiandrogen cover. In a "testosterone booster" story, the flare is the only part anyone mentions.
| Outcome | Gonadorelin | Triptorelin |
|---|---|---|
| Approved uses | A – diagnostic testing of pituitary function; pulsatile therapy in certain hypothalamic infertility | A – advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty |
| Mechanism | B – stimulation of the HPG axis when pulsatile | A – downregulation of the HPG axis |
| "Testosterone / fertility boosting" framing | D – extrapolated, not established | F – contradicts the mechanism |
The two failed framings get different grades for a reason. For gonadorelin, the "boost" framing borrows real endocrinology but drops the method that makes it work: supervised, pulsatile delivery. Continuous or mistimed dosing can suppress the axis instead. For triptorelin, there's no method that rescues the framing. Sustained suppression is what the drug is for.
| Gonadorelin | Triptorelin | |
|---|---|---|
| What it is | Synthetic natural GnRH | Long-acting GnRH agonist |
| Half-life | Very short | Long (depot forms) |
| Delivery that works | Pulsatile | Sustained |
| Net effect on the axis | Stimulates (if pulsatile) | Suppresses (after flare) |
| Brands | Varies by market | Decapeptyl, Trelstar, Diphereline |
| Expected effects | Defined clinical uses | Hypogonadism by design: bone density, mood, sexual function, menopausal-type symptoms |
Agents that act on the hormone axis are scrutinised in sport. Athletes, especially men, should check both compounds against the current WADA Prohibited List.
Does triptorelin raise testosterone? Only briefly, during the initial flare. Sustained action then shuts testosterone production down. That shutdown is why it is approved for prostate cancer.
Is gonadorelin the same as triptorelin? No. Both act on the GnRH receptor, but gonadorelin is the natural hormone with a very short half-life, and triptorelin is a long-acting analogue. Their delivery and net effect are opposite.
Can gonadorelin boost testosterone? That framing is graded D. It is extrapolated from approved endocrinology that depends on supervised pulsatile delivery, and it is not established for casual use.
What is triptorelin approved for? Advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. All of these rely on suppression.
Does Vallydia publish doses? No.
Gonadorelin and triptorelin are a lesson in why a mechanism has to be read in full. The same receptor, signalled in pulses, switches the axis on. Signalled constantly, it switches it off. Gonadorelin's "boost" claim is a half-truth missing its method. Triptorelin's is the opposite of the truth.
Same key, same lock – and it turns the other way when you don't let go.
Vallydia does not sell, supply or link to either compound.
How we separate evidence levels: how we grade · how we grade.
Vallydia sells its own cosmetic serums, and some ingredients discussed here belong to the same categories as those products. Assessments are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Brand and trade names appearing in these articles are the property of their respective owners and are used only to identify the product or ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor. Where we judge a claim, we are judging the published evidence for that claim — not making a statement about the company that makes it.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.